You may think that with a price-to-sales (or "P/S") ratio of 2.7x JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) is a stock worth checking out, seeing as almost half of all the Pharmaceuticals companies in China have P/S ratios greater than 3.6x and even P/S higher than 7x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.

See our latest analysis for JiangSu WuZhong Pharmaceutical Development

How JiangSu WuZhong Pharmaceutical Development Has Been Performing

With revenue growth that's superior to most other companies of late, JiangSu WuZhong Pharmaceutical Development has been doing relatively well. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.

How Is JiangSu WuZhong Pharmaceutical Development's Revenue Growth Trending?

In order to justify its P/S ratio, JiangSu WuZhong Pharmaceutical Development would need to produce sluggish growth that's trailing the industry.

Retrospectively, the last year delivered an exceptional 53% gain to the company's top line. However, the latest three year period hasn't been as great in aggregate as it didn't manage to provide any growth at all. Accordingly, shareholders probably wouldn't have been overly satisfied with the unstable medium-term growth rates.

Turning to the outlook, the next year should generate growth of 9.2% as estimated by the four analysts watching the company. That's shaping up to be materially lower than the 167% growth forecast for the broader industry.

With this in consideration, its clear as to why JiangSu WuZhong Pharmaceutical Development's P/S is falling short industry peers. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.

What We Can Learn From JiangSu WuZhong Pharmaceutical Development's P/S?

Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

As expected, our analysis of JiangSu WuZhong Pharmaceutical Development's analyst forecasts confirms that the company's underwhelming revenue outlook is a major contributor to its low P/S. Shareholders' pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

The company's balance sheet is another key area for risk analysis. Take a look at our free balance sheet analysis for JiangSu WuZhong Pharmaceutical Development with six simple checks on some of these key factors.

If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.